The effect of prostaglandin analogs and prostamide on central corneal thickness

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 1, 2009, Pages 51-53

  Hatanaka, Marcelo ^a   Vessani, Roberto M ^a   Elias, Isalina R ^a   Morita, Celso ^a   Susanna Jr , Remo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG EFFECT; EYE EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OPEN ANGLE GLAUCOMA; TREATMENT OUTCOME; VISUAL FIELD;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CORNEA; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC;

EID: 61749097687     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0125     Document Type: Article

References (22)

1. Goldmann, H., and Schmidt, T. About applanation tonometry. Ophthalmologica 134:221-42, 1957.
2. Doughty, M.J., and Zaman, M.L. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv. Ophthalmol. 44:367-408, 2000.
3. Singh, R.P., Goldberg, I., Grahan, S.L., et al. Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension. J. Glaucoma. 10:206-10, 2001.
4. Wu, L.L., Suzuki, Y., Ideta, R., et al. Central corneal thickness of normal tension glaucoma patients in Japan. Jpn. J. Ophthalmol. 44: 643-647, 2000.
5. Gordon, M.O., Beiser, J.A., Brandt, J.D., et al. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:714-720, 2002.
6. Birkedal, H.H. From tadpole collagenase to a family of matrix metalloproteinases. J. Oral Pathol. 17:445-451, 1989.
7. Wossner, J.F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:2145-2154, 1991.
8. Cawston, T. Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Mol. Med. Today 4:130-137, 1998.
9. Dollery, C.M., McEwan, J.R., and Henney, A.M. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863-868, 1995.
10. Vaalamo, M., Weckroth, M., Puolakkainen, P., et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br. J. Dermatol. 135:52-59, 1996.
11. Garrana, R.M., Zieske, J.D., and Assouline, M. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. Invest. Ophthalmol. Vis. Sci. 40:1266-1270, 1999.
12. Fini, M.E., and Girard, M.T. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest. Ophthalmol. Vis. Sci. 31:1779-1788, 1990.
13. Maeda, M., Vanlandingham, B.D., Ye, H., et al. Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy. Curr. Eye Res. 17:836-843, 1998.
14. Chang, J.H., Kook, M.C., Lee, J.H., et al. Effects of synthetic inhibitor of metalloproteinase and cyclosporine A on corneal haze after excimer laser photorefractive keratectomy in rabbits. Exp. Eye Res. 66:348-396, 1998.
15. Wagoner, M.D. Chemical injuries of the eye: Current concepts in pathophysiology and therapy. Surv. Ophthalmol. 41:275-313, 1997.
16. Weinreb, R.N., and Lindsey, J.D. Metalloproteinase gene transcription in human ciliary muscule cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:716-722, 2002.
17. Weinreb, R.N. Enhancement of scleral macromolecular permeability with prostaglandins. Trans. Am. Ophtahlmol. Soc. 99:319-323, 2001.
18. Mietz, H., Schlotzer-Schrehardt, U., Strassfeld, C., et al. Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. 42:679-687, 2001.
19. Viestenz, A., Martus, P., Schlötzer-Schrehardt, U., et al. Impact of prostaglandin F2-alpha aalogues and carbonic anhydrase inihibitors on central cornal thickness: A cross-sectional study on 403 eyes. Klin. Monatsbl. Augenheilkd. 221:753-756, 2004.
20. Stefan, C., Dumitrica, D.M., Tebeanu, E., et al. Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95-99, 2007.
21. Sen, E., Nalcacioglu, P., Yazici, A., et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398-402, 2008.
22. Harasymowycz, P.J., Papamatheakis, D.G., Ennis, M., et al. For the Travoprost Central Corneal Thickness Study Group. Relationship between travoprost and central corneal thickness in ocular ypertension and open-angle glaucoma. Cornea 26:34-41, 2007.